Breaking News

Symbiosis Expands Capabilities with BSL-2 Manufacturing Upgrade

Allows the CMO to meet the needs of the expanding viral vector cell and gene therapy market.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Symbiosis Pharmaceutical Services, a contract manufacturing organization (CMO) specializing in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, has expanded its capabilities to handle novel and emerging treatments, such as viral based gene- and oncolytic-therapies.   Headquartered in Stirling, UK, Symbiosis has completed a physical and regulatory upgrade to its existing manufacturing suites to enable the safe manufacture of biopharmaceutical products which require biosafe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters